Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

This study is currently recruiting participants.
Verified December 2012 by Women and Infants Hospital of Rhode Island
Information provided by (Responsible Party):
Carolyn McCourt, Women and Infants Hospital of Rhode Island Identifier:
First received: February 9, 2011
Last updated: December 26, 2012
Last verified: December 2012

This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.

Condition Intervention Phase
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Biological: Panitumumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.

Resource links provided by NLM:

Further study details as provided by Women and Infants Hospital of Rhode Island:

Primary Outcome Measures:
  • Overall response rate, measured by RECIST criteria [ Time Frame: Every 8 weeks while on-study ] [ Designated as safety issue: No ]
    Documentation of known measurable or evaluable disease parameters after every 2 cycles of treatment. If any patient is withdrawn for the study prior to completion of therapy a repeat evaluation will be done at that time.

Secondary Outcome Measures:
  • Adverse Events, measured by Active Version of the NCI Common Toxicity Criteria [ Time Frame: before each cycle of treatment until resolution ] [ Designated as safety issue: Yes ]
    Adverse events (AEs) will be recorded during the duration of the trial, whether or not the events are considered related to medication. All AEs considered to be related to trial therapy will be followed for resolution, including into the post-treatment period.

Estimated Enrollment: 35
Study Start Date: February 2011
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Panitumuab and Gemcitabine Biological: Panitumumab
Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.

Detailed Description:

Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality in women, with more than 22,000 deaths per year in the United States alone. Due to the lack of effective screening strategies and subtle early symptoms, eighty percent of newly diagnosed patients have disease that is advanced. Despite cytoreductive surgery and adjuvant paclitaxel-based and platinum-based chemotherapy, 5-year survival rates continue to be less than 40%. For patients who become resistant to the platinum compounds (defined as progressive disease while on a platinum-based chemotherapy regimen (refractory) or within 6 months of completing a platinum-based chemotherapy regimen (resistant)),the outlook is particularly poor, and often heralds multi-drug resistant disease.

At the present time, the management of ovarian cancer in the platinum refractory disease state is limited to palliative intent. Patients with advanced, bulky tumors, poor performance status and nutritional compromise are unlikely to respond to therapy and may be best served by supportive care. The clinical management of refractory disease requires both patience and persistence. A patient with platinum refractory disease is begun on one of the agents with activity and an evaluation of response is made every 6-8 weeks of therapy. As long as the patient shows no signs of disease progression, the therapy can be continued unless there is unacceptable toxicity. When progressive disease is observed, another of the list of available agents can be used. It is likely that patients will receive multiple single agents during the chronic phase of their illness. Every effort should be made to balance disease response with toxicity and quality of life.

Based on this rational, this trial will be conducted to evaluate the safety and efficacy of panitumumab, a human antibody targeted to the EGF-R, and Gemcitabine, in treating women with recurrent platinum-refractory/resistant EOC. Our aim is to determine the safety and feasibility of gemcitabine and panitumumab therapy in this population and once completed, to proceed with an efficacy study using an expanded cohort.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
  • Prior first line therapy with a platinum and taxane based combination as adjuvant therapy
  • Measurable disease defined by RECIST criteria
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • age > 18
  • Karnofsky performance status > 70
  • Up to three prior lines of cytotoxic therapy in the setting of recurrent disease.
  • Estimated life expectancy of at least 3 months
  • Women of child-bearing potential must have a negative pregnancy test
  • Adequate hematopoietic function defined as:

    • ANC ≥ 1500/mm3
    • Platelets ≥ 100,000/mm3
    • Hemoglobin ≥ 9 g/dL
    • Magnesium ≥ lower limit of normal
    • Calcium ≥ lower limit of normal
  • Adequate renal and hepatic function defined as:

    • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
    • SGOT ≤ 3 times ULN
    • Alanine aminotransferase (ALT) ≤3xULN (if liver metastases ≤5xULN)
    • Alkaline phosphatase ≤ 3 times ULN
    • Creatinine ≤ 1.5 mg/dL times ULN
    • Creatinine clearance ≤ 50 mL/min

Exclusion Criteria:

  • Prior anti-EGFr antibody therapy (e.g., cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib)
  • Prior treatment with gemcitabine
  • Radiotherapy ≤ 14 days prior to enrollment.
  • More than three lines of systemic chemotherapy for recurrent or advanced disease. Prior hormonal therapy is allowed.
  • Prior immunotherapy, or experimental or approved proteins/antibodies
  • Female subject is pregnant or breast-feeding.
  • Patient has received other investigational drugs within 28 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Prior treatment with panitumumab
  • Concurrent uncontrolled illness
  • Ongoing or active infection
  • History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers, curatively resected non-melanoma skin cancer
  • Psychiatric illness or social situation that would preclude study compliance.
  • History or known presence of central nervous system (CNS) metastasis
  • Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine)
  • Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) < 1 year before randomization
  • History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan
  • Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
  • Major surgery within 28 days or minor surgery within 14 days of study enrollment
  Contacts and Locations
Please refer to this study by its identifier: NCT01296035

Contact: Carolyn M McCourt, MD 401-453-7520
Contact: Carol Berk, RN 401-453-7520

United States, Rhode Island
Women & Infants' Hospital Recruiting
Providence, Rhode Island, United States, 02905
Contact: Carol Berk, RN    401-274-1122   
Contact: Wendy Young, RN    401-274-1122   
Sponsors and Collaborators
Women and Infants Hospital of Rhode Island
Principal Investigator: Carolyn McCourt, MD Women & Infants' Hospital
  More Information

No publications provided

Responsible Party: Carolyn McCourt, Dr. Carolyn McCourt, Women and Infants Hospital of Rhode Island Identifier: NCT01296035     History of Changes
Other Study ID Numbers: WIH 20050782
Study First Received: February 9, 2011
Last Updated: December 26, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Women and Infants Hospital of Rhode Island:
recurrent ovarian cancer
platinum-refractory ovarian cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Fallopian Tube Diseases
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents processed this record on April 16, 2014